🔗 Share this article

Given that the United States proceeds with historic changes to its vaccination recommendations, one figure has surfaced in a surprising turn: Høeg, a US-based sports physician and epidemiologist who initially gained attention by expressing skepticism about Covid vaccines throughout the pandemic and has concentrated on alleged fatalities following COVID-19 vaccination in her short tenure at the FDA.

Scheduled Overhauls to Pediatric Vaccine Schedule

Public health authorities had intended to unveil sweeping revisions to the childhood vaccine schedule recently, bringing the US with Denmark’s national calendar, it is understood – a major change that would put the US out of step with many the world with insufficient data for benefit. The planned update has been delayed until the new year.

Instead of the top vaccines chief, Høeg is listed to address the audience at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a closer partnership between the drug and biologics branches as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it suggests a increased emphasis upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting specific pediatric vaccine recommendations in the US in order to be more similar to Denmark, a nation with nationalized medicine and a citizenry about the size of the state of Wisconsin.

To date comments, she has persisted in emphasizing on immunizations – usually the purview of Prasad, head of the FDA’s CBER – as opposed to medication approval.

Concerns Over Qualifications

Høeg has no apparent experience in medication creation, approval processes or leadership, which has been typical for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the necessary background” for overseeing the CDER, remarked Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in managing a major agency. She has no expertise in pharmaceutical oversight.”

Former heads of the center would “understand regulatory frameworks and the underlying principles of drug development”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that prior appointees who ran the center have had.”

The drug center has an vast range of responsibilities at the agency, Woodcock emphasized.

“Many people just pays attention on the novel medication approvals, but the generic program clears numerous generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and each of these need to be managed,” she noted. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a major management component to the job, which manages in excess of 5,000 staff members. “It is a huge leadership role, if you perform it correctly,” Woodcock said.

Response and Controversial Policies

Regarding concerns about Høeg’s qualifications and whether this appointment represents greater collaboration among agency officials on immunizations, a press secretary said that the “questions stem from incorrect assumptions”.

“Her experience aligns with the functions of her role,” the representative stated, noting the months Høeg spent guiding the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s controversial fast-track approval initiative, a controversial rapid medication authorization process that apparently concerned her former heads. “How are these therapies being picked for this expedited pathway? Who is making the choices?” Howard said. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he said, “the FDA appears to be shifting towards laxer regulations of pharmaceuticals, with the exception of immunizations.”

Established Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a more established, if troubling, track record, Howard said. She released a analysis using unconfirmed public submissions to assess the incidence of myocarditis following COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccines are riskier than they are.

Part of her “wish list” for the current government featured altering guidelines for novel immunizations and halting “unnecessary” vaccines, she said after the election on a online show. At the FDA, Høeg has reportedly suggested preventing adolescent males from receiving COVID-19 vaccinations.

“She is an complete ideologue who starts off with her beliefs and reverse-engineers to fit the evidence in a very misleading, dishonest manner,” Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined fellow dissenters, {like|